Aeglea Bio Therapeutics Inc (AGLE) to Release Earnings on Thursday
Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) is scheduled to be posting its quarterly earnings results after the market closes on Thursday, March 23rd. Analysts expect Aeglea Bio Therapeutics to post earnings of ($0.46) per share for the quarter.
Shares of Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) opened at 8.03 on Tuesday. Aeglea Bio Therapeutics Inc has a one year low of $3.66 and a one year high of $12.75. The firm’s market cap is $107.84 million. The firm’s 50-day moving average price is $5.51 and its 200 day moving average price is $5.80.
Separately, Zacks Investment Research lowered Aeglea Bio Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, January 10th.
Your IP Address:
In related news, major shareholder Orbimed Advisors Llc purchased 109,300 shares of the firm’s stock in a transaction that occurred on Tuesday, February 21st. The stock was acquired at an average price of $5.16 per share, for a total transaction of $563,988.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Aeglea Bio Therapeutics Company Profile
Aeglea BioTherapeutics, Inc is a biotechnology company, which is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. The Company’s product pipeline includes AEB1102, AEB3103, AEB2109 and AEB4104. Its lead product candidate, AEB1102, is engineered to degrade the amino acid arginine and is being developed to treat over two extremes of arginine metabolism, including arginine excess in patients with Arginase I deficiency, an IEM, as well as some cancers, which have shown to have a metabolic dependence on arginine.
Receive News & Stock Ratings for Aeglea Bio Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics Inc and related stocks with our FREE daily email newsletter.